These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7419398)

  • 1. Mixed ligand chelates and plutonium poisoning.
    Humphreys ER; Stones VA
    Health Phys; 1980 Jul; 39(1):103-5. PubMed ID: 7419398
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined reticuloendothelial stimulation and long-term, intermittent DTPA therapy in poisoning by polymeric plutonium. ANL-7409.
    Rosenthal MW; Smoler HM; Lindenbaum A
    ANL Rep; 1967; ():180. PubMed ID: 5308231
    [No Abstract]   [Full Text] [Related]  

  • 3. Mixed ligand chelate therapy for plutonium and cadmium poisoning.
    Schubert J; Derr SK
    Nature; 1978 Sep; 275(5678):311-3. PubMed ID: 211429
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic and therapeutic studies of plutonium. IV. ANL-7535.
    Lindenbaum A; Rosenthal MW; Lund CJ; Russell JJ; Smoler MH; Moretti ES; Brown H
    ANL Rep; 1968 Dec; ():60-5. PubMed ID: 5306872
    [No Abstract]   [Full Text] [Related]  

  • 5. [On the comparative efficacy of desferrioxamine and DTPA as agents for the elimination of plutonium in poisoned rats].
    Truhaut R; Boudène C; Lutz M; Métivier H
    Arch Mal Prof; 1966 Sep; 27(9):669-76. PubMed ID: 5983123
    [No Abstract]   [Full Text] [Related]  

  • 6. [Value of standard Licam (C) in plutonium radiocontamination].
    Gerasimo P; Duserre C; Ducousso R; Metivier H
    Ann Pharm Fr; 1987; 45(3):189-94. PubMed ID: 3434970
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of accidental intakes of plutonium and americium: guidance notes.
    Ménétrier F; Grappin L; Raynaud P; Courtay C; Wood R; Joussineau S; List V; Stradling GN; Taylor DM; Bérard P; Morcillo MA; Rencova J
    Appl Radiat Isot; 2005 Jun; 62(6):829-46. PubMed ID: 15799861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research in the complexon series. I. Detoxicant capacity of Ca-DTPA in experimental chronic plutonium poisoning in rats. II. Influence of the repeated intravenous administration of Ca-DTPA on the elimination of trace elements in rats. 3. Preliminary results of the study, in rats, of the modalities of calcium elimination after Ca45-DTPA injection].
    Truhaut R; Boudène C; Lutz M
    Ann Biol Clin (Paris); 1966; 24(3):419-39. PubMed ID: 5932716
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of ascorbate ions in DTPA treatment after contamination by mixed plutonium dioxide-sodium burning products.
    Métvier H; Masse R; Nolibé D; Nénot JC; Lafuma J
    Health Phys; 1977 May; 32(5):450-2. PubMed ID: 881345
    [No Abstract]   [Full Text] [Related]  

  • 10. Intracellular plutonium: removal by liposome-encapsulated chelating agent.
    Rahman YE; Rosenthal MW; Cerny EA
    Science; 1973 Apr; 180(4083):300-2. PubMed ID: 4633691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can mixed ligand therapy completely remove plutonium from the body?
    Volf V
    Health Phys; 1980 Aug; 39(2):364-6. PubMed ID: 7429860
    [No Abstract]   [Full Text] [Related]  

  • 12. Plutonium ( 239 Pu) toxicity diagnosis and therapy.
    Norwood WD
    J Occup Med; 1972 Jan; 14(1):37-44. PubMed ID: 5058618
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective dose of DTPA, spaced at 3-day intervals, in removal of skeletal plutonium. ANL-7535.
    Rosenthal MW; Russell JJ; Moretti ES; Lindenbaum A
    ANL Rep; 1968 Dec; ():65-7. PubMed ID: 5306873
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of early DTPA treatments in two types of plutonium exposures in humans.
    Lagerquist CR; Hammond SE; Putzier EA; Piltingsrud CW
    Health Phys; 1965 Nov; 11(11):1177-80. PubMed ID: 5867870
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of DTPA therapy on long-term effects of retained monomeric plutonium: comparison with polymeric plutonium.
    Osenthal MW; Lindenbaum A
    Radiat Res; 1967 Jul; 31(3):506-21. PubMed ID: 6027890
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA IND approval for Zn-DTPA, new clinical agent for decorporation therapy of actinides.
    Lushbaugh CC; Washburn LC
    J Nucl Med; 1979 Jan; 20(1):73. PubMed ID: 219167
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA.
    Sérandour AL; Grémy O; Fréchou M; Renault D; Poncy JL; Fritsch P
    Radiat Res; 2008 Aug; 170(2):208-15. PubMed ID: 18666819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumors in rats that have received pentacin after the administration of plutonium-239].
    Bukhtoiarova EM; Lemberg VK; Erokhin RA; Beliaev IuA
    Vopr Onkol; 1968; 14(8):71-6. PubMed ID: 5247174
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of mixed-ligand complexes on retention and distribution of radioniobium in mice.
    Gachályi A; Naményi J; Szegedi I; Varga LP
    Radiat Res; 1987 Nov; 112(2):312-7. PubMed ID: 3685258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Ca-DTPA as a treatment for plutonium inhaled in mixed oxide aerosols of plutonium and sodium.
    Stather JW; Rodwell P
    Health Phys; 1980 Nov; 39(5):801-5. PubMed ID: 7204032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.